These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 4823626

  • 1. Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man.
    Ablad B, Borg KO, Johnsson G, Regårdh CG, Sölvell L.
    Life Sci; 1974 Feb 16; 14(4):693-704. PubMed ID: 4823626
    [No Abstract] [Full Text] [Related]

  • 2. Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.
    Collste P, Seideman P, Borg KO, Haglund K, von Bahr C.
    Clin Pharmacol Ther; 1979 Apr 16; 25(4):423-7. PubMed ID: 428186
    [Abstract] [Full Text] [Related]

  • 3. Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol.
    Collste P, Borg KO, Aström H, von Bahr C.
    Clin Pharmacol Ther; 1979 Apr 16; 25(4):416-22. PubMed ID: 34497
    [No Abstract] [Full Text] [Related]

  • 4. Central haemodynamic effects in man of intravenous d-alprenolol during rest and exercise.
    Ekelund LG, Melcher A, Orö L.
    Eur J Clin Pharmacol; 1971 Sep 16; 3(4):198-203. PubMed ID: 5151303
    [No Abstract] [Full Text] [Related]

  • 5. Duration of action of beta-blocking drugs.
    Carruthers SG, Kelly JG, McDevitt DG, Shanks RG, Walsh MJ.
    Br Med J; 1973 Apr 21; 2(5859):177. PubMed ID: 4144672
    [No Abstract] [Full Text] [Related]

  • 6. Lack of biological interaction of alprenolol and salicylate in man.
    Johnsson G, Regårdh CG, Sölvell L.
    Eur J Clin Pharmacol; 1973 Jun 21; 6(1):9-14. PubMed ID: 4764375
    [No Abstract] [Full Text] [Related]

  • 7. Absorption, distribution and excretion of alprenolol in man, dog and rat.
    Bodin NO, Borg KO, Johansson R, Obianwu H, Svensson R.
    Acta Pharmacol Toxicol (Copenh); 1974 Oct 21; 35(4):261-9. PubMed ID: 4479578
    [No Abstract] [Full Text] [Related]

  • 8. Steady-state plasma concentrations of alprenolol in man.
    Rawlins MD, Collste P, Frisk-Holmberg M, Lind M, Ostman J, Sjöqvist F.
    Eur J Clin Pharmacol; 1974 Aug 23; 7(5):353-6. PubMed ID: 4419005
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.
    Regårdh CG.
    Acta Pharmacol Toxicol (Copenh); 1975 Aug 23; 37(1):1-39. PubMed ID: 237402
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.
    Collste P, Haglund K, Frisk-Holmberg M, Rawlins MD.
    Eur J Clin Pharmacol; 1976 Jun 15; 10(2):85-8. PubMed ID: 9292
    [Abstract] [Full Text] [Related]

  • 11. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.
    Johnsson G, Regårdh CG, Sölvell L.
    Acta Pharmacol Toxicol (Copenh); 1975 Jun 15; 36(Suppl 5):31-44. PubMed ID: 1094802
    [No Abstract] [Full Text] [Related]

  • 12. Metabolism of alprenolol in liver microsomes, perfused liver and conscious rat.
    Borg KO, Eklund B, Skånberg I, Wallborg M.
    Acta Pharmacol Toxicol (Copenh); 1974 Sep 15; 35(3):169-79. PubMed ID: 4479244
    [No Abstract] [Full Text] [Related]

  • 13. Kinetic studies of dose-dependent metabolism of alprenolol: in vitro and in vivo studies in different species.
    Skånberg I, Borg KO, Fellenius E, Hoffmann KJ, von Bahr C, Moldéus P.
    Acta Pharmacol Toxicol (Copenh); 1979 Jan 15; 44(1):28-35. PubMed ID: 760385
    [Abstract] [Full Text] [Related]

  • 14. [Comparison between alprenolol in tablet form (Aptin) and in "sustained release" form (Aptin Durules) in angina pectoris].
    Lorentzen F, Jorgensen P, Nielsen E, Nyberg G, Hvidt S.
    Ugeskr Laeger; 1973 Jul 02; 135(27):1431-8. PubMed ID: 4585750
    [No Abstract] [Full Text] [Related]

  • 15. Comparative studies on central factors contributing to the hypotensive action of propranolol, alprenolol, and their enantiomers.
    Offerhaus L, van Zwieten PA.
    Cardiovasc Res; 1974 Jul 02; 8(4):488-95. PubMed ID: 4426059
    [No Abstract] [Full Text] [Related]

  • 16. Study of the metabolic pathways of alprenolol in man and the dog using stable isotopes.
    Hoffmann KJ, Arfwidsson A, Borg KO, Skånberg I.
    Biomed Mass Spectrom; 1978 Nov 02; 5(11):634-40. PubMed ID: 749958
    [Abstract] [Full Text] [Related]

  • 17. Effects of alprenolol on central hemodynamics and exercise tolerance in patients with angina pectoris.
    Jonsson B, Olsson AG, Orö L.
    Cardiology; 1973 Nov 02; 58(3):152-61. PubMed ID: 4149331
    [No Abstract] [Full Text] [Related]

  • 18. Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.
    Vedin JA, Wilhelmsson CE, Werkö L.
    Br Heart J; 1973 Dec 02; 35(12):1285-92. PubMed ID: 4586374
    [No Abstract] [Full Text] [Related]

  • 19. Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs.
    Himori N, Ishimori T, Izumi A, Hiramatsu Y.
    Arch Int Pharmacodyn Ther; 1977 Jan 02; 225(1):152-65. PubMed ID: 15525
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two adrenergic beta-receptor blocking agents, alprenolol and propranolol, in treatment of angina pectoris.
    Heterington DJ, Comerford MB, Nyberg G, Besterman EM.
    Br Heart J; 1973 Mar 02; 35(3):320-33. PubMed ID: 4632566
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.